Regenxbio Inc (RGNX) Stock Analysis
Verdict: HOLD
Severe cash burn of $126.4M/yr against $34.5M cash balance forces impending equity dilution or debt restructuring before RGX-314 Phase III data.
Investment score: 40/100
Analysis as of
Is Regenxbio Inc stock worth reviewing? AI model thesis
The model score of 40/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Regenxbio Inc opportunities and risks
What speaks for RGNX
- RGX-314 Phase III pivotal trial in wet AMD targets a multi-billion dollar anti-VEGF market
What speaks against RGNX
- Imminent cash runway depletion threatening massive shareholder dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RGNX | n/a | 2.4x | n/a | 54.2% | -112.6% | -60.5% |
| TECX | n/a | 0.0x | n/a | 0.0% | 0.0% | -13.8% |
| PRME | n/a | 133.0x | n/a | -1025.6% | -4613.1% | -28.9% |
| VSTM | n/a | 7.3x | n/a | 86.7% | -231.6% | -25.4% |
| ZURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.7% |
| Peer median | n/a | 3.7x | n/a | 0.0% | -115.8% | -21.6% |
Frequently asked questions about Regenxbio Inc (RGNX)
Is RGNX stock a good investment?
The cached TradeMates AI model rates Regenxbio Inc as HOLD with an investment score of 40/100. The model score of 40/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is RGNX stock a buy?
The TradeMates model verdict for RGNX is HOLD with an investment score of 40/100. Treat this as a model signal to review, not a personal buy recommendation.